Korean J Hematol.  2010 Jun;45(2):79-80. 10.5045/kjh.2010.45.2.79.

Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator?

• Kim HJ

• KMID: 2083535
• DOI: http://doi.org/10.5045/kjh.2010.45.2.79

Abstract

No abstract available.

Reference

1. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22:624–633. PMID: 14726504.

2. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005; 106:2854–2861. PMID: 15994285.

3. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106:3733–3739. PMID: 16076867.

4. Suzuki R, Onizuka M, Kojima M, et al. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol. 2007; 86:422–428. PMID: 18192111.

5. Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol. 2009; 90:1–5. PMID: 19484332.

6. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106:3740–3746. PMID: 16051734.

7. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1,485 adult patients with acute myeloid leukemia (AML). Blood. 2006; 107:4011–4020. PMID: 16455956.

8. Kim YK, Kim HN, Lee SR, et al. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol. 2010; 45:36–45.

9. Schlenk RF, Döhner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol. 2009; 16:98–104. PMID: 19468271.

10. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111:2776–2784. PMID: 17957027.